APRINOIA Therapeutics

1:15 PM - 1:30 PM, Tuesday, June 4, 2019 ・ Theater 2
APRINOIA discovers and develops first-in-class diagnostics and therapeutics for Alzheimer’s Disease (AD) and other tau-associated neurodegenerative diseases (Tauopathies). We achieve our mission by building comprehensive internal drug discovery and development capabilities and integrative collaborations with world-class scientists, research institutions and pharmaceutical companies to bring innovative ideas and scientific discoveries to life. Our goal is to create novel products to meet critical patient needs, including novel imaging-based diagnostic tools to improve the detection of occurrence, progression, and regression of neurological diseases; and novel therapies to improve the treatment of human neurological conditions.
Ticker:
Not Provided.
Exchange:
Not Provided.
Company Type:
Company Website:
Company HQ State:
Not Provided.
Company HQ Country:
Taiwan
Year Founded:
2015
Main Therapeutic Focus:
Lead Product in Development:
18F Tau PET Imaging Tracer (APN-1607)
Development Phase of Primary Product:
Number Of Unlicensed Products (For Which You Are Seeking Partners):
5 projects in pipeline
Speaker
photo
CEO
APRINOIA Therapeutics